Hypertension. 2005;45:222-226
Published online before print January 10, 2005,
doi: 10.1161/01.HYP.0000154229.97341.d2
(Hypertension. 2005;45:222.)
© 2005 American Heart Association, Inc.
Evaluation of Carotid-Femoral Pulse Wave Velocity
Influence of Timing Algorithm and Heart Rate
Sandrine C. Millasseau;
Andrew D. Stewart;
Sundip J. Patel;
Simon R. Redwood;
Philip J. Chowienczyk
From the Cardiovascular Division, GKT School of Medicine, Kings College London, United Kingdom.
Correspondence to Dr P.J. Chowienczyk, Department of Clinical Pharmacology, St. Thomas Hospital, Lambeth Palace Rd, London SE1 7EH, UK. E-mail phil.chowienczyk{at}kcl.ac.uk
 |
Abstract
|
|---|
Carotid-femoral pulse wave velocity (PWV), a measure of arterial
stiffness, is determined from the time taken for the arterial
pulse to propagate from the carotid to the femoral artery. Propagation
time is measured variously from the foot of the waveform or
point of maximum upslope. We investigated whether these methods
give comparable values of PWV at rest, during ß-adrenergic
stimulation, and pacing-induced tachycardia. In subjects at
rest (n=43), values obtained using the foot-to-foot method (SphygmoCor
system) were 1.7±0.75 m/s (mean±SD) greater than
those obtained using the maximum slope (Complior system) at
a mean value of 12 m/s. Isoprotenerol (0.5 to 1.5 µg/min;
n=10), and pacing (in subjects with permanent pacemakers; n=11)
increased heart rate but had differential effects on systolic
blood pressure and pulse pressure. The increase in heart rate
produced by isoprotenerol (18±3 bpm) and pacing (40 bpm)
was associated with an increase in PWV measured using both systems
(increases of 0.7±0.2 m/s and 0.9±0.2 m/s for
SphygmoCor and Complior, respectively, during isoprotenerol
and increases of 2.1±0.5 m/s and 1.1±0.2 m/s for
SphygmoCor and Complior, respectively, during pacing, each
P<0.001).
Reanalysis of waveforms recorded from the Complior system using
the foot-to-foot method produced similar values of PWV to those
obtained with the SphygmoCor, confirming that the difference
between these systems was attributable to the timing algorithm
rather than other aspects of signal acquisition. Carotid-femoral
PWV is critically dependent on the method used to determine
propagation time, but this does not account for variation of
PWV with heart rate.
Key Words: risk factors compliance pulse heart rate
 |
Introduction
|
|---|
Stiffening of the aorta and large elastic arteries is a biophysical
manifestation of vascular aging with important prognostic implications.
It is elevated in conditions such as renal failure, diabetes,
and hypertension, and in each of these conditions, it is predictive
of subsequent cardiovascular events.
16 Pulse wave velocity
(PWV) is related to the intrinsic elasticity of the arterial
wall and its anatomic dimensions by the Moens-Korteweg equation.
7,8 It is recommended as one of the best methods for measuring stiffness
9,10 and is the measure used in most large clinical studies.
16 PWV is usually determined over the carotid-femoral region by
measuring the propagation time of the pressure pulse from the
carotid to femoral arteries. The 2 systems in common use, the
SphygmoCor (AtCor) and Complior (Artech) differ with respect
to their sensor technology and the algorithm used for calculating
the pulse propagation time. The SphygmoCor device uses an arterial
tonometer for recording pressure waveforms. Propagation time
is measured from the foot of the carotid waveform to that of
the femoral waveform using sequential recordings referenced
to the ECG (
Figure 1a). In the Complior system, carotid and
femoral waveforms are recorded simultaneously using mechanotransducers,
and timing is referenced to the point of maximum systolic upstroke
(
Figure 1b). The influence of the different methods for calculating
pulse propagation time on values of PWV obtained using the 2
instruments is unknown, but it has been suggested that this
might account for a variation of PWV with heart rate.
11,12 In
preliminary studies, we observed a marked difference between
values of PWV obtained with the SphygmoCor and Complior devices.
The purpose of the present study was to determine whether this
is attributable to the method for measuring pulse propagation
time and also to determine whether it might account for variation
of PWV with heart rate. We compared measurements of PWV obtained
with the 2 devices at rest and before and after an increase
in heart rate induced by ß-adrenergic stimulation
and by pacing.

View larger version (13K):
[in this window]
[in a new window]
|
Figure 1. a, Measurement of carotid to femoral propagation time using the intersecting tangent foot-to-foot algorithm as used in the SphygmoCor system. The foot of the pressure waveform is identified by the intersection of the tangent to the maximum systolic upstroke with the horizontal line through the minima of the waveform. b, Measurement of propagation time from the point of maximum upstroke of the signal as used in the Complior system.
|
|
 |
Methods
|
|---|
Measurements of carotid-femoral propagation time (transit time
[TT]) and PWV obtained using the Complior and SphygmoCor systems
were compared in subjects at rest (study 1), during intravenous
infusion of isoprotenerol (study 2), and pacing (study 3). The
studies were approved by the local research ethics committee,
and all subjects gave written informed consent.
Measurements obtained using the SphygmoCor system (TTSphyg and PWVSphyg) were determined with the SphygmoCor software using the intersecting tangent algorithm to identify the foot of the waveform (Figure 1a).13 Those obtained with the Complior system (TTComp and PWVComp) were determined using the Complior software (timing referenced to the point of maximum systolic upstroke; Figure 1b).13,14 In addition, in-house software (MatLab; Mathworks) was used to calculate the propagation time from Complior waveforms using the intersecting tangent method (TTComp* and PWVComp*; Figure 1a). Care was taken to place the transducers over the same point of the arteries, and the same distance (sternal notch to femoral artery) was used to calculate PWV. A minimum of 3 readings using each device was obtained by the same operator with the different devices used in random order for alternate measurements.
Because the influence of the timing algorithm could depend on the rate of change of the systolic upstroke of the pulse (dP/dt, calculated as the increment above diastolic pressure of the first systolic peak/shoulder, divided by the time to this peak/shoulder), this was computed from the carotid waveform obtained while measuring PWVSphyg. This waveform was also used to calculate carotid systolic blood pressure and carotid pulse pressure (which differ from brachial pressures as a result of peripheral amplification15), assuming brachial and carotid mean and diastolic pressures are equal.16
Study 1: Comparison of Resting Values of TT and PWV
Study 1 was performed in 43 subjects with a range of risk factors for cardiovascular disease or established cardiovascular disease (Table 1) and included subjects who also participated in studies 2 and 3. After 15 minutes of resting supine, brachial blood pressure was measured using an oscillometric device (Omron 705CP; Omron), and measurements of TT and PWV were obtained.
Study 2: Comparison of PWV During Intravenous Infusion of Isoprotenerol
Study 2 was performed in 10 healthy volunteers (Table 1). After insertion of an intravenous cannula and after 15 minutes of rest supine, during which subjects received intravenous saline, baseline measurements of blood pressure and PWV were determined as described above. Subjects then received a stepped infusion of isoprotenerol (0.5, 1, and 1.5 µg/min, each dose for 20 minutes). Blood pressure and PWV were determined during the last 15 minutes of each dose.
Study 3: Comparison of PWV During Pacing-Induced Tachycardia
This study was performed in 11 subjects with permanent pacemakers (Table 1). Eight subjects had dual-chamber pacemakers and 3 had single chamber (VVI) pacemakers. The reasons for pacemaker insertion were complete heart block (n=8), sick sinus syndrome (n=2), and vasovagal syncope (n=1). After 15 minutes of rest supine, the pacemaker was programmed to ventricular rates of 80, 100, and 120 bpm. After 5 minutes at each step, measurements of blood pressure and PWV were repeated over a 15-minute period.
Statistical Analysis
Subject characteristics are summarized as means±SD and results as means±SEM (except where otherwise stated). Repeatability was assessed by calculating within-subject coefficient of variation (WCV)17 for repeated measurements. Values of TT and PWV were compared using a Bland-Altman plot with calculation of the mean difference and SD of the difference. ANOVA for repeated measures was used to test for changes in hemodynamic measurements during infusion of isoprotenerol and pacing-induced tachycardia. The significance level was set at P<0.05.
 |
Results
|
|---|
Study 1: Comparison of Resting Values of TT and PWV
For repeated measurements of TT, WCV was 5.6%, 6.8%, and 8.9%,
for TT
Sphyg, TT
Comp, and TT
Comp*, respectively. For PWV, WCV
obtained from the SphygmoCor and Complior devices were similar,
irrespective of the timing algorithm used: WCV was 5.7%, 4.8%,
and 5.5% for PWV
Sphyg, PWV
Comp, and PWV
Comp*, respectively.
Values of TT
Sphyg were significantly lower than those of TT
Comp (mean difference±SD; 5.9±5.5 ms;
P<0.001;
Figure 2).
Because of the reciprocal relationship between PWV and TT,
this led to values of PWV
Sphyg significantly greater than those
of PWV
Comp (mean difference±SD; 0.91±1.07 m/s;
P<0.001), with the difference increasing with increasing
PWV (
Figure 3). At a mean PWV of 12 m/s, the difference was
1.7±0.75 m/s (mean±SD). However, when the intersecting
tangent algorithm was implemented on waveforms recorded by the
Complior device, values of PWV
Sphyg did not differ significantly
from those of PWV
Comp* (
Figures 2 and 3
).
Study 2: Comparison of PWV During Intravenous Infusion of Isoprotenerol
During infusion of isoprotenerol, heart rate, brachial and carotid systolic blood pressure, pulse pressure, and dP/dt increased significantly (Table 2). There was a small but significant increase in mean arterial pressure (4±1 mm Hg at the highest dose; P<0.01). As in study 1, mean values of PWVSphyg were greater than those of PWVComp at rest and remained greater during infusion of isoprotenerol (P<0.001). Both PWVSphyg and PWVComp increased significantly (by 0.7±0.2 m/s and 0.9±0.2m/s, respectively, at the highest dose; each P<0.001). Application of the intersecting tangent algorithm to waveforms obtained using the Complior resulted in similar values of PWV to those obtained by the SphygmoCor (Figure 4).
Study 3: Comparison of PWV During Pacing Induced Tachycardia
Brachial and carotid systolic blood pressure and dP/dt did not change significantly during pacing from 80 to 120 bpm (Table 3). Diastolic blood pressure increased by 7±1 mm Hg (P<0.001), with a corresponding increase in mean arterial pressure of 5±1 mm Hg (P<0.01). Mean values of PWVSphyg were consistently higher than values of PWVComp throughout the paced heart rate range (Figure 4; P<0.001). PWVSphyg and PWVComp increased by 2.1±0.5 m/s and 1.1±0.2 m/s, respectively (each P<0.001). Mean values of PWVComp* obtained by applying the intersecting tangent algorithm to Complior waveforms did not differ significantly from those of PWVSphyg (Figure 4).
 |
Discussion
|
|---|
The first major finding of the present study is a substantial
difference between values of PWV obtained using the SphygmoCor
and Complior systems attributable to a systematic difference
in TT. Because of the reciprocal relationship between PWV and
TT, values of PWV obtained using the SphygmoCor system are greater
than those obtained with the Complior and the difference increases
in proportion to the mean value of PWV. At a mean value of 12
m/s, the difference between the 2 devices is 1.7 m/s. Using
the coefficient relating PWV to age obtained in a healthy European
population,
18 this difference represents 27 years of vascular
aging. Such a difference could, in principle, arise from the
different transducers used in the 2 devices, difference between
simultaneous (Complior) or sequential/ECG-referenced (SphygmoCor)
recordings, or the different algorithms used to measure propagation
time. When the intersecting tangent algorithm was used to calculate
TT from waveforms recorded using the Complior, PWV values obtained
from the 2 devices were in agreement. This suggests that computation
of PWV is critically dependent on the algorithm used to determine
TT and that the contribution of other sources of variation is
relatively minor. Furthermore, within-subject variability was
similar for PWV
Sphyg and PWV
Comp, suggesting that sequential
acquisition of waveforms (SphygmoCor) does not contribute significantly
to random variation when hemodynamic conditions are stable.
Our study does not determine which of the 2 methods for measuring
propagation time is "correct." A comparison with a definitive
method would be ideal, but there is no consensus as to what
constitutes the definitive method.
10 However, there are theoretical
reasons to prefer using the foot of the pressure wave as identified
by the intersecting tangent method.
13 The foot of the wave is
least likely to be influenced by distortion of the pressure
waveform during its forward propagation through the arterial
tree attributable, for example, to pressure wave reflections.
12,13,15
The impact of using the foot of the pressure wave (identified by the intersecting tangent algorithm) versus the maximum upstroke might be expected to depend on the initial rate of change of the pulse waveform and hence on heart rate or ejection time. It has been suggested that the variation of PWV with heart rate that has been observed in studies using the Complior system19 but not in studies using the foot-to-foot method is an artifact related to the algorithm used to measure propagation time.11,12 To examine this, we studied the effects of intravenous isoprotenerol and pacing-induced tachycardia. The only consistent hemodynamic changes common to both interventions were a marked increase in heart rate and a small (
5 mm Hg) increase in mean arterial blood pressure. For both interventions, the increase in heart rate was associated with an increase in PWV irrespective of the device or algorithm used. Thus, although the use of different timing algorithms produces different values of PWV, it is unlikely to account for variation of PWV with heart rate.
Comparison with previous studies in which we have produced acute changes in blood pressure in the absence of changes in heart rate suggest that the increase in mean arterial pressure was too small to account for the observed change in PWV.20 Furthermore, an increase in PWV with heart rate, in the absence of any change in mean arterial blood pressure, has been observed in other studies.19,21 Therefore, the results of the present study in combination with these other studies are consistent with a true increase in arterial PWV associated with an increase in heart rate. However, it is likely that the size of the effect varies according to age, gender, and degree of aortic stiffening.22 The possible mechanism underlying such an increase in PWV with heart rate remains poorly understood. Visco-elastic properties of the arterial wall have been invoked to explain variation of PWV with heart rate,21 but ORourke et al have argued that this explanation is unlikely.11,12 They point out that at the high frequencies that determine the foot of the wave, visco-elastic properties of the arterial wall vary little with heart rate.2325 However, these experiments on visco-elastic properties of the arterial wall were performed in canine arteries, and we are not aware of any data in the human aorta. The positive correlation between PWV and heart rate observed in cross-sectional studies22,26,27 could be attributable to a similar effect to that observed in this study or to a chronic effect leading, for example, to increased PWV secondary to tissue fatigue.
It is important to note the limitations of this study relating to the interpretation of the changes in PWV seen during ß-adrenergic stimulation and pacing. Because changes in heart rate were also accompanied by changes in mean arterial pressure or pulse pressure, we cannot be certain that heart rate is the primary determinant of such changes. However, change in blood pressure would not be expected to influence the difference in PWV attributable to the timing algorithm. Thus, the fact that changes in heart rate were accompanied by changes in PWV calculated using different algorithms suggests that the influence of heart rate on PWV described in previous studies is unlikely to be explained by the timing algorithms used.
Perspectives
There are substantial differences between values of PWV obtained using the SphygmoCor and Complior systems, the 2 commercially available devices described in the recent task force recommendation on measuring arterial stiffness using PWV.9 The size of the difference is clinically significant, being equivalent to >2 decades of vascular aging for subjects with a moderate degree of aortic stiffening (PWV >12 m/s). Values obtained from the 2 devices cannot be used interchangeably, and the system used to measure PWV must be considered when estimating cardiovascular risk from measurements of PWV. The difference between the 2 systems is attributable to the algorithm used to calculate TT. However, the use of different algorithms does not explain variation of PWV with increases in heart rate produced by ß-adrenergic stimulation or pacing. Further studies to determine the mechanism underlying variation of PWV with heart rate are required.
 |
Acknowledgments
|
|---|
S.C.M. was funded by Micro Medical Ltd., and A.D.S. was supported
by a grant from the Charitable Foundation of Guys and
St. Thomas Hospital. We are grateful to the pacing technicians
from the Department of Cardiology, St. Thomas Hospital,
for their assistance with this study.
Received September 21, 2004;
first decision October 7, 2004;
accepted December 14, 2004.
 |
References
|
|---|
- Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME. Impact of aortic stiffness on survival in end-stage renal disease. Circulation. 1999; 99: 24342439.[Abstract/Free Full Text]
- Boutouyrie P, Tropeano AI, Asmar R, Gautier I, Benetos A, Lacolley P, Laurent S. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension. 2002; 39: 1015.[Abstract/Free Full Text]
- Laurent S, Katsahian S, Fassot C, Tropeano AI, Gautier I, Laloux B, Boutouyrie P. Aortic stiffness is an independent predictor of fatal stroke in essential hypertension. Stroke. 2003; 34: 12031206.[Abstract/Free Full Text]
- Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, Ducimetiere P, Benetos A. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001; 37: 12361241.[Abstract/Free Full Text]
- Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation. 2002; 106: 20852090.[Abstract/Free Full Text]
- Meaume S, Benetos A, Henry OF, Rudnichi A, Safar ME. Aortic pulse wave velocity predicts cardiovascular mortality in subjects >70 years of age. Arterioscler Thromb Vasc Biol. 2001; 21: 20462050.[Abstract/Free Full Text]
- Moens AI. Die Pulskurve. Leiden, ed. 1878.
- Korteweg DJ. Über die Fortpflanzungsgesschwindigkeit des Schalles in elastischen Rohren. Annals of Physics and Chemistry (NS). 1878; 5: 520537.
- Pannier BM, Avolio AP, Hoeks A, Mancia G, Takazawa K. Methods and devices for measuring arterial compliance in humans. Am J Hypertens. 2002; 15: 743753.[CrossRef][Medline]
[Order article via Infotrieve]
- ORourke MF, Staessen JA, Vlachopoulos C, Duprez D, Plante GE. Clinical applications of arterial stiffness; definitions and reference values. Am J Hypertens. 2002; 15: 426444.[CrossRef][Medline]
[Order article via Infotrieve]
- Hayward CS, Avolio AP, ORourke MF. Arterial pulse wave velocity and heart rate. Hypertension. 2002; 40: e8e9.[Medline]
[Order article via Infotrieve]
- ORourke MF, Hayward CS. Arterial stiffness, gender and heart rate. J Hypertens. 2003; 21: 487490.[CrossRef][Medline]
[Order article via Infotrieve]
- Chiu YC, Arand PW, Shroff SG, Feldman T, Carroll JD. Determination of pulse wave velocities with computerized algorithms. Am Heart J. 1991; 121: 14601470.[CrossRef][Medline]
[Order article via Infotrieve]
- Asmar R, Benetos A, Topouchian J, Laurent P, Pannier B, Brisac A-M, Target R, Levy BI. Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies. Hypertension. 1995; 26: 485490.[Abstract/Free Full Text]
- Nichols WW, ORourke MF. McDonalds Blood Flow in Arteries. Theoretical, Experimental and Clinical Principles. London, UK: Arnold; 1998.
- van Bortel LM, Balkestein EJ, Heijden-Spek JJ, Vanmolkot FH, Staessen JA, Kragten JA, Vredeveld JW, Safar ME, Struijker Boudier HA, Hoeks AP. Non-invasive assessment of local arterial pulse pressure: comparison of applanation tonometry and echo-tracking. J Hypertens. 2001; 19: 10371044.[CrossRef][Medline]
[Order article via Infotrieve]
- Quan H, Shih WJ. Assessing reproducibility by the within-subject coefficient of variation with random effects model. Biometrics. 1996; 52: 11951203.[CrossRef][Medline]
[Order article via Infotrieve]
- Asmar R. Factors influencing pulse wave velocity. In: Asmar R, ed. Arterial Stiffness and Pulse Wave Velocity. Paris, France: Elsevier; 1999: 5788.
- Lantelme P, Mestre C, Lievre M, Gressard A, Milon H. Heart rate: an important confounder of pulse wave velocity assessment. Hypertension. 2002; 39: 10831087.[Abstract/Free Full Text]
- Stewart AD, Millasseau SC, Kearney MT, Ritter JM, Chowienczyk PJ. Effects of inhibition of basal nitric oxide synthesis on carotid-femoral pulse wave velocity and augmentation index in humans. Hypertension. 2003; 42: 915918.[Abstract/Free Full Text]
- Haesler E, Lyon X, Pruvot E, Kappenberger L, Hayoz D. Confounding effects of heart rate on pulse wave velocity in paced patients with a low degree of atherosclerosis. J Hypertens. 2004; 22: 13171322.[CrossRef][Medline]
[Order article via Infotrieve]
- Albaladejo P, Laurent P, Pannier B, Achimastos A, Safar M, Benetos A. Influence of sex on the relation between heart rate and aortic stiffness. J Hypertens. 2003; 21: 555562.[CrossRef][Medline]
[Order article via Infotrieve]
- Bergel DH. The dynamic elastic properties of the arterial wall. J Physiol (Lond). 1961; 156: 458469.[Free Full Text]
- Callaghan FJ, Babbs CF, Bourland JD, Geddes LA. The relationship between arterial pulse-wave velocity and pulse frequency at different pressures. J Med Eng Technol. 1984; 8: 1518.[Medline]
[Order article via Infotrieve]
- Li JK, Melbin J, Riffle RA, Noordergraaf A. Pulse wave propagation. Circ Res. 1981; 49: 442452.[Abstract/Free Full Text]
- Sa Cunha R, Pannier B, Benetos A, Siché J-P, London GM, Mallion JM, Safar ME. Association between high heart rate and high arterial rigidity in normotensive and hypertensive subjects. J Hypertens. 1997; 15: 14231430.[CrossRef][Medline]
[Order article via Infotrieve]
- McGrath BP, Liang YL, Kotsopoulos D, Cameron JD. Impact of physical and physiological factors on arterial function. Clin Exp Pharmacol Physiol. 2001; 28: 11041107.[CrossRef][Medline]
[Order article via Infotrieve]
This article has been cited by other articles:

|
 |

|
 |
 
A. Qasem and A. Avolio
Determination of Aortic Pulse Wave Velocity From Waveform Decomposition of the Central Aortic Pressure Pulse
Hypertension,
February 1, 2008;
51(2):
188 - 195.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. D. Stewart, B. Jiang, S. C. Millasseau, J. M. Ritter, and P. J. Chowienczyk
Acute Reduction of Blood Pressure by Nitroglycerin Does Not Normalize Large Artery Stiffness in Essential Hypertension
Hypertension,
September 1, 2006;
48(3):
404 - 410.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Paini, P. Boutouyrie, D. Calvet, A.-I. Tropeano, B. Laloux, and S. Laurent
Carotid and Aortic Stiffness: Determinants of Discrepancies
Hypertension,
March 1, 2006;
47(3):
371 - 376.
[Abstract]
[Full Text]
[PDF]
|
 |
|